U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
<iframe src="https://statesidedaily.com/embed/cluster/38d33fc863d78c3cd09dbb9e9135f3d5213eb812" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology"></iframe>
